Search Results - "Sawanobori, Tomoko"

Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study by Ito, Sadayoshi, Kashihara, Naoki, Shikata, Kenichi, Nangaku, Masaomi, Wada, Takashi, Okuda, Yasuyuki, Sawanobori, Tomoko

“…Background Esaxerenone has potential renoprotective effects and reduces the urinary albumin-to-creatinine ratio (UACR) in patients with diabetic kidney disease…”
Get full text

The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial by Okuda, Yasuyuki, Ito, Sadayoshi, Kashihara, Naoki, Shikata, Kenichi, Nangaku, Masaomi, Wada, Takashi, Sawanobori, Tomoko, Taguri, Masataka

“…Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are recommended as first-line drugs for hypertension with diabetic…”
Get full text

Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS‐3150) and sodium–glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies by Shikata, Kenichi, Ito, Sadayoshi, Kashihara, Naoki, Nangaku, Masaomi, Wada, Takashi, Okuda, Yasuyuki, Sawanobori, Tomoko, Sugimoto, Kotaro

“…Aims/Introduction We evaluated the effect of co‐administration of esaxerenone and a sodium–glucose cotransporter 2 (SGLT2) inhibitor on the magnitude of serum…”
Get full text

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial by Ito, Sadayoshi, Shikata, Kenichi, Nangaku, Masaomi, Okuda, Yasuyuki, Sawanobori, Tomoko

“…The progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors…”
Get full text

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial by Ito, Sadayoshi, Kashihara, Naoki, Shikata, Kenichi, Nangaku, Masaomi, Wada, Takashi, Okuda, Yasuyuki, Sawanobori, Tomoko

“…Diabetic kidney disease is an important complication of type 2 diabetes. In a phase 2b study, adding esaxerenone to renin-angiotensin system inhibitors dose…”
Get full text